Showing 4119 results for "als"

Blink reflex test may be biomarker to diagnose, monitor ALS: Study

A test that assesses the electrical activity associated with blinking may help speed the diagnosis of amyotrophic lateral sclerosis (ALS) and monitor disease progression in people with the condition, a study found. Findings showed that certain electrical waves can significantly distinguish people with ALS from healthy controls or…

ALS symptoms: Difficulty breathing and swallowing

Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease that affects the muscles involved in swallowing and breathing, potentially leading to issues such as malnutrition and weight loss, along with aspiration and lung infections.

ALS research center planned to open at Vanderbilt University

A neuroscientist with a specialty in amyotrophic lateral sclerosis (ALS) is joining the faculty at Vanderbilt University Medical Center (VUMC) and will establish an ALS research center at the Nashville school. Véronique Belzil, PhD, whose work is focused on developing tailored treatments for people with ALS, also will serve…

£14.5M awarded toward ALS, other neurodegenerative disease projects

A partnership between LifeArc and the UK Dementia Research Institute (UK DRI) is awarding £14.5 million (about $18.2 million) to seven research projects aimed at developing new tests, treatments, and devices for neurodegenerative diseases. “Our partnership with UK DRI allows us to identify and back the most promising translational…

SOL-257 gene therapy improves outcomes in 2 ALS mouse models

SOL-257, an experimental one-time gene therapy, was well tolerated and significantly improved disease outcomes in two distinct mouse models of amyotrophic lateral sclerosis (ALS). Developed by Sola Biosciences, SOL-257 is designed to clear the toxic TDP-43 protein that accumulates and forms clumps in ALS nerve cells, contributing to…

Lead PAS-003 candidate chosen to target key protein in ALS

Pasithea Therapeutics has selected a lead candidate for its PAS-003 program, which is intended to target a “velcro-like” protein to treat amyotrophic lateral sclerosis (ALS). The new therapy is a humanized monoclonal antibody that potently inhibits the alpha-5/beta-1 integrin protein. It was selected after extensive screening and characterization studies…

ALS and exercise

Exercise can be beneficial for people with amyotrophic lateral sclerosis (ALS), helping to preserve muscle strength and mobility for as long as possible, and enhancing overall quality of life.